We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AstraZeneca’s Imfinzi With Tremelimumab Increased Overall Survival in Liver Cancer Patients
AstraZeneca’s Imfinzi With Tremelimumab Increased Overall Survival in Liver Cancer Patients
Liver cancer patients who received AstraZeneca’s blockbuster human monoclonal antibody Imfinzi (durvalumab) paired with the company’s anti-CTLA4 antibody tremelimumab in a phase 3 trial lived longer.